janiecbros As investors search for disruptive companies within the biotech sector, it is helpful to consider disruptive technologies that necessarily precede them. Specifically, the revolutionary CRISPR/Cas9 gene-editing platform has recently made headlines with FDA approval of a revolutionary drug named Casgevy. This therapy, pioneered by CRISPR Therapeutics (NASDAQ: CRSP), amazingly recognizes the correct segment of DNA to edit by using a piece of RNA as a guide. The Cas9 protein then cuts the patient's D ...

CRISPR Therapeutics AG (CRSP) closed the latest trading day at $53.91, indicating a +0.34% change from the previous session's end. The stock's performance was behind the S&P 500's daily gain of 1.02%. Meanwhile, the Dow gained 0.4%, and the Nasdaq, a tech-heavy index, added 2.03%.Heading into today, shares of the company had lost 21.17% over the past month, lagging the Medical sector's loss of 5.2% and the S&P 500's loss of 3.15% in that time.Analysts and investors alike will be keeping a close eye on the p ...

CRISPR Therapeutics AG (CRSP) closed at $55.02 in the latest trading session, marking a -0.05% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.87%. Elsewhere, the Dow gained 0.67%, while the tech-heavy Nasdaq added 1.11%.Coming into today, shares of the company had lost 23.13% in the past month. In that same time, the Medical sector lost 6.67%, while the S&P 500 lost 3.97%.Market participants will be closely following the financial results of CRISPR Therapeutics AG ...

股价表现 - Crispr Therapeutics AG (NASDAQ:CRSP) 股价在2月22日达到两年多来的高点后，现在已经下跌了2.8%，目前为每股56.35美元[1] - 过去一个月，CRSP股价下跌了20.8%，今年迄今为止的亏损率为9.6%[1] 技术指标 - Crispr Therapeutics 股票的14天相对强度指数（RSI）为18.2，处于“超卖”区域，通常表明会有短期反弹[3] - Crispr Therapeutics 股票的短期利空因子占流通股比例的17.6%，需要8天的交易量才能全部平仓[3] 波动性评估 - Crispr Therapeutics 股票的波动性评分（SVS）为86，表明该股票在过去12个月中超过了期权交易者的波动性预期，对于买方来说是一个好消息[4]

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this company have returned -19.5%, compared to the Zacks S&P 500 composite's -1.1% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has lost 8.3%. The key question now is: What could be the ...

CRISPR Therapeutics - CRISPR Therapeutics 有望在未来实现市值翻倍，目前市值约为51亿美元，未来十年有望增长至100亿美元以上[3] - CRISPR Therapeutics 与 Vertex Pharmaceuticals 合作的基因疗法获得 FDA 批准，治疗输血依赖性β-地中海贫血和镰状细胞病，被认为是这些疾病的功能性治愈方案，可能带来高达40亿美元的年收入[4] Eli Lilly - Eli Lilly 在糖尿病药物市场表现强劲，拥有多项重要临床和监管突破，市值达7250亿美元，有望在未来六年内翻倍[8] - Eli Lilly 的药物 Zepbound 获得批准，有望成为未来的增长驱动力，同时在肿瘤学、免疫学和神经科学领域也有多个潜力药物[9] Viking Therapeutics - Viking Therapeutics 在肥胖药物市场和非酒精性脂肪肝治疗市场有巨大潜力，市值近80亿美元，有望在未来十年内翻倍[13] - Viking Therapeutics 的 VK2735 和 VK2809 有望在全球肥胖药物市场和非酒精性脂肪肝治疗市场占据一席之地，预计市场规模将在2030年达到1000亿美元以上[15][17]

公司发展 - CRISPR Therapeutics AG在过去9年中发展迅速，现在已经准备好迎接未来9年的增长[4] - CRISPR Therapeutics AG目前在进行七项不同的试验，这将决定公司未来的发展方向[4] 财务情况 - CRISPR Therapeutics AG每年的运营支出约为4亿至5亿美元，但能够以更低的成本完成其他公司需要更高成本才能完成的工作[6] 合作伙伴关系 - CRISPR Therapeutics AG的合作伙伴Vertex已经在美国和欧洲设立了多个中心，为CASGEVY的推广做好准备[13] 产品研发 - CRISPR Therapeutics AG正在研发针对骨髓的靶向调理剂，这有望提高CASGEVY的采纳率并扩大患者群体[21] - 公司认为功能性持久性比单纯持久性更为重要，因此专注于提高CAR-T细胞的活性[31] 市场前景 - 公司在淋巴瘤领域设定了25%至30%的持久性完全缓解率作为成功标准[36] - 公司在自身免疫疾病领域投入大量资源，认为AlloCAR-T在自身免疫疾病中具有优势[41]

公司股价表现 - CRISPR Therapeutics AG (CRSP) 最新收盘价为 $65.19，较前一天上涨了 +1.72% [1] - 公司股价在过去一个月内下跌了 16.57%，落后于医疗行业的 4.03% 损失和标普500指数的 1.65% 增长 [2] 财务表现 - 分析师预计 CRISPR Therapeutics AG 将在即将发布的财报中报告每股收益为 -$1.63，较去年同期下降了 143.28% [3] - Zacks Consensus Estimate 预测公司的净销售额为 $8.31 百万美元，较去年同期下降了 91.69% [4] - Zacks Consensus Estimates 预测公司全年每股亏损为 -$6.24，营收为 $105.41 百万美元，较去年分别下降了 -221.65% 和 -71.6% [5] 估值变动和评级系统 - 分析师对 CRISPR Therapeutics AG 的最新估值变动反映了短期业务趋势的变化，正面的估值变动表明分析师对公司业绩和利润潜力的信心 [6] - 研究表明估值变动与即将到来的股价表现直接相关，公司的 Zacks Rank 评级系统整合了这些估值变动，提供了一个功能性的评级系统 [7] - Zacks Rank 评级系统从 1 (强烈买入) 到 5 (强烈卖出)，自 1988 年以来，排名第一的股票年均回报率达到 +25% [8] 行业排名 - 医疗 - 生物医学和遗传学行业属于医疗行业，目前的 Zacks Industry Rank 为 83，在所有行业中排名前 33% [9] - Zacks Industry Rank 通过测量各行业内个股的平均 Zacks Rank 来评估各行业群体的实力，研究显示排名前 50% 的行业胜过后 50% 的行业 [10] 下一步行动 - 请关注 Zacks.com，以了解这些影响股价的指标，以及在接下来的交易日中的更多信息 [11]

生物技术公司新产品批准 - Iovance Biotherapeutics和CRISPR Therapeutics都是生物技术公司，近期获得了新产品的批准[1] - Iovance的产品Amtagvi是一种治疗晚期黑色素瘤的疗法，利用患者自身免疫系统攻击癌细胞[2] - CRISPR Therapeutics专注于基于CRISPR技术的基因编辑疗法，已获得世界首个基于CRISPR技术的产品Casgevy的监管批准[6]

Biopharma stocks have been among the most popular and well-performing stocks this year. With recent trends in weight loss drugs and clinical advancements in treating illnesses, this market is set for significant advances this year. There’s no better time for investors to look into the companies leading the charge and the stocks expected to perform best. These three biopharma stocks have products capitalizing on the surging demand for the latest, most popular drugs this year.We’ll detail the developments of ...